A Surge in Weight-Loss Drugs Caused Investors to Lose Their Appetite for Food-Related Stocks in Q3
Much as artificial intelligence (AI) dominated headlines and investor mindshare earlier in the year, in the third quarter, the market became fixated on the impacts of GLP-1 drugs. These drugs (GLP is short for glucagon-like peptide) include Novo Nordisk's Ozempic and Wegovy, Eli Lilly's Mounjaro...
Read More